A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade®) in Healthy Subjects
Crossref DOI link: https://doi.org/10.1007/s40259-015-0150-5
Published Online: 2015-11-17
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Shin, Donghoon
Kim, Youngdoe
Kim, Yoo Seok
Körnicke, Thomas
Fuhr, Rainard
License valid from 2015-11-17